Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer: Description of the Surgical Technique and Initial Results
|
|
- Jocelyn Stephens
- 5 years ago
- Views:
Transcription
1 european urology 52 (2007) available at journal homepage: Surgery in Motion Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer: Description of the Surgical Technique and Initial Results Jean-Baptiste Lattouf a, *, Avi Beri a, Stephan Jeschke a, Wolfgang Sega b, Karl Leeb a, Günter Janetschek a a Department of Urology, Krankenhaus der Elisabethinen, Linz, Austria b Department of Pathology, Krankenhaus der Barmherzigen Schwestern, Linz, Austria Article info Article history: Accepted April 24, 2007 Published online ahead of print on May 2, 2007 Keywords: Laparoscopy Lymph node excision Neoplasm staging Prostatectomy Prostatic neoplasms Abstract Objective: In patients with prostate cancer, extended pelvic lymph node dissection (eplnd) yields a higher number of lymph node metastases (LNM) than standard pelvic lymph node dissection (PLND) of the obturator fossa only. We describe our laparoscopic technique of extended lymph node dissection and provide the number and locations of positive lymph nodes from our experience. Methods: In a total of 35 selected patients with clinically localized prostate cancer, laparoscopic eplnd was performed prior to laparoscopic radical prostatectomy. The template included the genitofemoral nerve up to the bifurcation of the common iliac artery and down to the epigastric artery. In the split and roll technique the internal and external iliac arteries including the bifurcation and the external iliac vein were completely mobilized. After freeing the obturator nerve, the entire lymph node package was released from the pelvic side wall. Results: Mean operative time was 90 min/patient. The complications were two temporary and reversible neurapraxias (ischiatic nerve and obturator nerve), one deep vein thrombosis, and two lymphoceles. One lymphocele healed conservatively; the second was marsupialized laparoscopically. Eleven (31.4%) patients had lymph node metastases; their mean prostate-specific antigen (PSA) level was ng/ml (range: ng/ml) and their median Gleason sum in biopsy was 7 (range: 6 8). Mean size of the LNM was mm (range: 0.2 8). In 5 of the 11 patients with LNM these were detected exclusively outside the obturator fossa. LNM were in the obturator fossa only in two (one bilateral), around the external iliac artery only in two, around the internal iliac artery only in two, and around the external iliac artery and internal iliac only in one patient. Conclusions: Laparoscopic eplnd can be combined with laparoscopic radical prostatectomy. Standardization of the technique facilitates surgery to a great extent. e-plnd detects LNM in a significant number of patients. The majority of LNM are outside the obturator fossa. The transperitoneal approach allows a wide exposure and is the most important factor to enable successful eplnd. # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. KH Elisabethinen Linz, Fadingerstrasse 1, A-4010 Linz, Austria. Tel ; Fax: address: jean-baptiste.lattouf@umontreal.ca (J.-B. Lattouf) /$ see back matter # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 1348 european urology 52 (2007) Introduction Table 1 Patient demographics Since the advent of the prostate-specific antigen (PSA) era, the finding of lymph node metastasis in operative candidates with prostate cancer has decreased significantly [1 6]. However, most of the reported data pertains to a dissection template limited to the obturator fossa. This template is somewhat in disregard of earlier studies on the lymph drainage of the prostate, which specifically show that drainage is mainly to the internal iliac nodes [7]. Using extended pelvic lymph node dissection (eplnd), the incidence of lymph node metastases (LNM) has been recently reported to be higher than that in the limited dissection. In fact, more than half of metastases to lymph nodes are found outside the standard template of dissection [8 10]. Compounding this finding are reports of a possible survival benefit in patients with minimal LNM dating as far back as 1982, although this remains the subject of intense controversy [11 15]. Laparoscopic PLND has already been described for the limited template PLND [16 18], but to our knowledge, technical description of extended laparoscopic PLND has been rarely reported and no standardized approach is commonly adopted. We herein report our preliminary experience with laparoscopic eplnd with up to 2 yr of follow-up in a selected cohort of patients, and propose a detailed, step-by-step surgical approach to this procedure. No. of patients 35 Mean age, yr (median, range) 63 (63, 48 76) Mean preoperative PSA, ng/ml 16.5 (11.7, ) (median, range) Gleason score, no. (%) 4 2 (5.7%) 5 3 (8.6 %) 6 13 (37.1%) 7 11 (31.4%) 8 5 (14.3%) 9 1 (2.9) Stage ct1 23 (65.7%) ct2 11 (31.4%) ct3 1 (2.9%) PSA = prostate-specific antigen Description of the technique All interventions were performed by a single surgeon (G.J.) using a transperitoneal approach in all but one case (2.8%), which was done at the beginning of our experience and for which a preperitoneal approach was used (the Discussion provides further details). We used five ports for both approaches: a 10-mm port for the camera through a periumbilical incision, a 11/12-mm port midway between the umbilicus and pubic symphysis, two 5-mm ports at the right and left iliac fossa midway between umbilicus and anterior superior iliac spine, and the last 5-mm port on the right side superolateral to the previous port. 2. Patients and methods 2.1. Patient population All patients in our center undergoing radical prostatectomy are enrolled in an ongoing prospective, sentinel lymph node study of which initial results have already been published [19]. Extended unilateral or bilateral PLND is performed on these patients for two indications, respectively: (1) no sentinel lymph node is detected on the ipsilateral pelvic sidewall intraoperatively or (2) the frozen section of the sentinel lymph node is positive for metastatic prostate cancer. Thus, every patient receives systematically bilateral PLND (either sentinel or extended). Between April 2004 and November 2005, a total of 174 patients underwent radical prostatectomy in our center, of whom 69 satisfied the criteria for inclusion in the sentinel lymph node study (PSA 5 ng/ml or Gleason score 6). Of this last subset, 35 men had an indication for an eplnd and were included in this study. Mean age was 63 yr (median: 63 yr; range: yr) and mean preoperative PSA was 16.5 ng/ml (median: 11.7 ng/ml; range: ng/ml). Table 1 presents the patient demographics. None of the patients had received preoperative hormonal therapy. Fig. 1 Dissection template of extended pelvic lymph node dissection in prostate cancer. (A) External iliac packet; (B) obturator packet; (C) internal iliac packet. 1, aorta; 2, common iliac artery; 3, external iliac artery; 4, internal iliac artery; 5, external iliac vein; 6, obturator vessels; 7, obturator nerve; 8, obliterated umbilical artery; 9, epigastric vessels; 10, psoas muscle; 11, genitofemoral nerve.
3 european urology 52 (2007) Fig. 2 (A) Anatomic landmarks of the dissection from an endoscopic view. (B) 1, vas deferens; 2, ureter; 3, common iliac artery; 4, obliterated medial umbilical ligament; 5, Douglas pouch. The template of the lymph node dissection included the genitofemoral nerve anterolaterally, the internal iliac artery posteromedially, the bifurcation of the common iliac artery cranially, and the origin of the epigastric vessels caudally. The dissection was limited laterally by the pelvic wall musculature. Fig. 1 illustrates the template and Fig. 2 shows the main anatomic landmarks form and endoscopic view. The specific steps of the dissection were as follows: (1) Incision of the peritoneum laterally to the medial umbilical ligament and parallel to the external iliac artery (Fig. 3). (2) Identification and transection of the vas as it is encountered (Fig. 4). (3) Development of the preperitoneal fat plane down to the superior pubic ramus (Fig. 5). (4) Tracing the medial umbilical ligament down to its junction with the internal iliac artery (Fig. 6) and identifying the ureter at its crossing with the superior vesical artery. (5) Identification of the bifurcation of the common iliac artery and the external iliac artery, as well as the external and internal iliac veins. (6) Identifying the genitofemoral nerve and isolating it along its course from the bifurcation of the common iliac artery to the origin of the epigastric vessels. (7) Splitting the fibrofatty tissue overlying the internal iliac artery and vein followed by the same maneuver for the external iliac artery and vein (Figs. 7 and 8). (8) After freeing the obturator nerve (Fig. 9), separating the aforementioned fibrofatty tissue from the lateral pelvic wall. (9) Ligating the remaining attached portions of the lymph node packets thus obtained using laparoscopic Endo-clips and removing the packets en bloc. Specimens were sent separately for the external iliac, obturator fossa, and internal iliac regions. In some cases where intracorporeal separation of the packet was not possible for the obturator fossa and internal iliac regions, packets from these regions were sent as one specimen to pathology. All patients underwent laparoscopic radical prostatectomy after their lymph node dissection. Biochemical recurrence on follow-up was defined as PSA 0.4 ng/ml [20 22] Pathologic examination Only one experienced pathologist (W.S.) performed the tissue examination. As mentioned, we make a point of sending Fig. 3 Incision of the peritoneum overlying the common iliac artery*.
4 1350 european urology 52 (2007) Fig. 4 (A) Transection of the vas deferens. (B) 1, obliterated medial umbilical ligament; 2, vas deferens. Fig. 5 (A) Dissection of the avascular plane lateral to the umbilical ligament down to the pubic bone. (B) 1, pubic bone; 2, obturator nerve; 3, pelvic wall musculature; 4, peritoneal incision (deflected). separate lymph node packages to maximize lymph node inspection. Specimens were dissected by the pathologist and examined macroscopically to identify all lymph nodes. Every specimen looking like a lymph node was then sectioned and examined. Microscopic postoperative histopathologic examination of the sentinel and nonsentinel lymph nodes included a standard protocol of step sections in 250-mm sequences (conventional hematoxylin and eosin staining) and Fig. 6 (A) Dissection of the umbilical ligament down to its origin on the internal iliac artery. (B) 1, internal iliac artery; 2, medial umbilical ligament; 3, peritoneal fold.
5 european urology 52 (2007) Fig. 7 (A) Splitting over the internal iliac vessels. (B) 1, internal iliac artery; 2, internal iliac vein. immunohistochemistry (pan-cytokeratin) of each third step, respectively. The histopathologic results for each lymph node were catalogued Statistical methods Only descriptive statistics are provided given the limited sample being studied. 3. Results A total of 47 pelvic sidewalls in 35 patients with eplnds were analyzed (unilateral, 23; bilateral, 12). Mean operative time for the lymph node dissection was 90 min/patient. Mean number of lymph nodes retrieved was 14/patient (median: 13; 95% confidence interval [CI] ). Eleven patients (31.4%) had metastasis to their pelvic lymph nodes. Mean metastasis size was 3.1 mm (median: 2.7 mm; 95%CI mm). Tables 2 and 3 show the distribution of metastatic lymph nodes according to pathologic staging and final Gleason score. The location and number of metastases per anatomic region are shown in Table 4. Of 11 patients with metastasis, 5 (45.5%) had their involved lymph node exclusively outside the obturator fossa and would have been under-staged by a limited dissection template. LNM were in the obturator fossa only in two patients (one bilateral), around the external iliac artery only in two patients, around the internal iliac artery only in two patients, and around the external iliac artery and internal iliac only in one patient. All interventions were accomplished laparoscopically and no conversion was necessary. Complications were limited to two (5.7%) temporary and reversible neurapraxias (ischiatic nerve and obturator nerve), as well as one (2.9%) deep vein thrombosis and two (5.7%) lymphoceles. One lym- Fig. 8 (A) Dissection of the external iliac vessels. (B) 1, common iliac artery; 2, external iliac artery; 3, internal iliac artery; 4, medial umbilical ligament; 5, obturator nerve; 6, external iliac vein; 7, external iliac node packet; 8, peritoneal incision.
6 1352 european urology 52 (2007) Fig. 9 (A) Splitting over the obturator nerve. (B) 1, obturator nerve; 2, external iliac vein; 3, pelvic wall musculature; 4, medial umbilical ligament (retracted medially); 5, obturator node packet. Table 2 Number of metastases according to pathologic stages Pathologic tumor stage No. of patients No. with metastases pt2 18 0/18 (0%) pt /17 (58.8%; CI 35 81%) pt4 0 CI = 95% confidence interval. phocele healed conservatively, and the second was marsupialized laparoscopically. Postoperative PSA follow-up was available up to 2 yr after dissection in 24 patients (68.5%). Of the patients with LNM, three (27.3%) experienced biochemical recurrence and were placed on hormonal treatment. The rest have experienced no recurrence after a mean follow-up of 12.8 mo (median: 9 mo; range: 3 24 mo). None of the patients with negative lymph node dissection have experienced recurrence after a mean follow-up of 6.9 mo (median: 6 mo; range: 3 18 mo). 4. Discussion PLND remains today a controversial issue when it comes to the indication, the extent, and the possible therapeutic value of the dissection. Many studies that have documented the incidence of lymph node metastasis in prostate cancer, before as well as after the PSA era, used a template limited to the obturator fossa [1 6]. Given the lower frequency of LNM that was noted in the PSA era using this limited dissection template (6 9%) [5,23,24], preclinical parameters were assessed to provide an indication of whether to proceed to lymph node dissection or not [4,23,25,26]. This was based on the common belief that PLND in prostate cancer patients undergoing prostatectomy is mainly done for staging and not curative reasons. Studies dating back as far as 25 yr ago have shown, however, that the main drainage of the prostate is to the internal iliac lymph nodes [7]. Furthermore, an increasing body of evidence suggests that more than half of the LNM occur outside Table 3 Number of metastases according to Gleason score Gleason score on prostatectomy specimen No. of patients No. with metastasis 5 2 0/ /14 (7.1%; CI %) /12 (33.3%; CI %) 8 5 4/5 (80%; CI %) 9 2 2/2 (100%) CI = 95% confidence interval. Table 4 Distribution of metastases per anatomic region Mean nodal count per patient (median, 95%CI) 14 (13, ) Metastases per anatomic region External iliac 5/144 (3.5%, CI %) Obturator fossa 6/133 (4.5%, CI 1 8%) Internal iliac 4/49 (8.2%, CI %) Obturator + internal iliac 1/67 (1.5%, CI 0 4.4%) Nonspecified 3/85 (3.5%, CI 0 7.4%) CI = 95% confidence interval.
7 european urology 52 (2007) the obturator fossa [8,19,27], bringing into question the conclusions drawn from previous data. As stated, what defines an extended lymph node dissection is a subject of controversy. Lymph node count has been suggested by some authors as a criterion for separating an extended from a limited dissection [28]. However, given that the node count is not available to the surgeon during the surgical procedure, we do not define an extended or a limited node dissection based on the number of nodes but solely on the template. This is why we include patients who, for instance, have fewer than 10 nodes in our analysis. This being said, our median node count is considered comparable to what is achieved with extended dissections, and patients with 10 lymph nodes or less account for only 13.8% of our population [8,9]. The rate of positive lymph nodes reported in open eplnd varies from 3.2% to 26.2%, depending on the population studied [8,9,27]. Our metastatic lymph nodes rate using laparoscopic eplnd was 31.4%, which is in accordance with studies treating highrisk patients with clinical T2 and T3 disease. We underline, however, the fact that this is a biased incidence related to our indications, because a number of these patients were known to have metastasis in their sentinel lymph node frozen section, which prompted the extended dissection. This may therefore be an overestimate of the incidence of metastasis in a highly selected population. On the other hand, the fact that we analyze patients having positive frozen section along with patients having no sentinel lymph node detected may artifactually decrease the estimated incidence of metastasis. Ideally, these two cohorts, with different risk profiles, should be separately analyzed. Given our limited initial numbers, however, we have decided to analyze them as a single cohort. The concordance of our finding with previously published results may imply that the pooled data of these extreme cohorts may actually represent a fair approximation of the average expected incidence of metastasis. We were able to reproduce the previously reported finding that a significant number of metastasis (namely, 45.5% in this study) were exclusively outside the obturator fossa and would therefore have been missed with a limited dissection. Furthermore, quality assurance reflected by the number of dissected lymph nodes per patient in our population compares favorably to what is published in open series, where median lymph nodes removed per patient varied from 11.6 to 20 [8,9]. Our series also compares well to laparoscopic eplnd series reporting this figure in the literature [29,30]. Our median number of lymph nodes resected was 13 and represents an underestimation of the total number of nodes that could be resected per patient using our technique. This is because we performed extended dissection on only one side in as many as 23 of 35 patients given that these patients were also involved in a sentinel lymph node study. It may be argued that patients in whom unilateral eplnd was performed should not be included in the analysis because the true nodal status in these patients is unknown. Our findings pertaining to sentinel lymph node dissection in prostate cancer have demonstrated, however, that when metastases are present, they exclusively occur in the sentinel node [19]. We therefore believe that no information is lost when eplnd is performed unilaterally in a patient who already had sentinel node dissection on the contralateral side. Although with limited numbers, this series shows that reliance on a PSA cut-off value of 10 as has been suggested in previous studies may still miss a significant number (13.3%) of patients with positive lymph nodes. Although we perform PLND at our institution solely for diagnostic reasons, some studies suggest, albeit with retrospective evidence, that the removal of micrometastasis may be curative in prostate cancer [11 14]. Therefore, 13.3% of false negatives may not be inconsequential. At the beginning of our experience, we attempted to approach laparoscopic eplnd using both transperitoneal and preperitoneal approaches. We soon realized, however, that the feasibility of the procedure relied on the type of surgical exposure that could only be achieved with the transperitoneal approach, especially with regard to the internal iliac vessels dissection. We also feel that placing a drain intraperitoneally at the end of procedure is an additional prophylactic measure against lymphocele formation because it keeps the communication between the intraperitoneal and extraperitoneal spaces patent. These considerations prompted us to adopt an exclusively transperitoneal approach in our subsequent patients. Overall complication rates vary from 4.1% to 22.4% for limited template PLND [2,25] and from 2% to 35% for eplnd [8,27]. Our complication rate in this series was 14.3%, which compares favorably to what is published for extended and even limited template PLND. The major drawbacks of this study are the limited number of patients, the limited follow-up as well as the highly selected patient population. However, our main intention was to show technical feasibility and proof of adequacy using quality control param-
8 1354 european urology 52 (2007) eters such as total lymph node count and complication rates, and to propose a standardized approach that will hopefully allow comparison in future studies. 5. Conclusion We have described a standardized approach to performing extended laparoscopic lymph node dissection in prostate cancer. This approach is feasible, and reproducible and yields comparable results to the open technique. Further studies with follow-up are needed to compare these two techniques. Conflicts of interest There are no commercial interests involved with this article. However, the production of the DVD has been sponsored by Olympus. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at doi: / j.eururo and via com. Subscribers to the printed journal will find the supplementary data attached (DVD). References [1] Fowler JE, Whitmore Jr WF. The incidence and extent of pelvic lymph node metastasis in apparently localized prostate cancer. Cancer 1981;47: [2] McDowel II CG, Johnson JW, Tenney DM, Johnson DE. Pelvic lymphadenectomy for staging clinically localized prostate cancer: indications, complications, and results in 217 cases. Urology 1990;35: [3] Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150: [4] Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994;151: [5] Petros JA, Catalona WJ. Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol 1992;147: [6] Danella JF, Dekernion JB, Smith RB, Steckel J. The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 1993;149: [7] Raghavaiah NV, Jordan Jr WP. Prostatic lymphography. J Urol 1979;121: [8] Bader P, Buckhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168: [9] Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172: [10] Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/ml and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006;97: [11] Zincke H, Utz DC, Myers RP, Farrow GM, Patterson DE, Furlow WL. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement. Urology 1982;19: [12] Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169: [13] Schmid HP, Mihatsch MJ, Hering F, Rutishauser G. Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Eur Urol 1997;31:11 6. [14] Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91: [15] Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68: [16] Gershman A, Daykhovsky L, Chandra M, Danoff D, Grundfest WS. Laparoscopic pelvic lymphadenectomy. J Laparoendosc Surg 1990;1:63 8. [17] Griffith DP, Schuessler WW, Nickell KG, Meaney JT. Laparoscopic pelvic lymphadenectomy for prostatic adenocarcinoma. Urol Clin North Am 1992;19: [18] Beer M, Staehler G, Dorsam J. Laparoscopic pelvic lymphadenectomy. Indications, technique, initial results. Chirurg 1991;62: [19] Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005;173: [20] Amling CL, Bergstralh LH, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2003;165: [21] Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007; 51: [22] Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical
9 european urology 52 (2007) prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24: [23] Bishoff JT, Reyes A, Thompson IM, et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 1995;45: [24] Partin AW, Kattan KW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1998;277: [25] Campbell SC, Klein EA, Levin HS, Piedmonte MR. Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 1995;46: [26] Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004;63: [27] Heidenreich A, Varga Z, VonKnobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167: [28] Briganti A, Chun FK-H, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006;50: [29] Touijer K, Guillonneau B. Laparoscopic radical prostatectomy: a critical analysis of surgical quality. Eur Urol 2006;49: [30] Wyler SF, Sulser T, Seifert HH, et al. Laparoscopic extended pelvic lymph node dissection for high risk prostate cancer. Urology 2006;68: Editorial Comment on: Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer: Description of the Surgical Technique and Initial Results Pierre I. Karakiewicz Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada H2X 3J4 pierre.karakiewicz@umontreal.ca Lattouf et al address the issue of lymph node metastases in men with clinically localized prostate cancer (PCa) and confirm the validity of extended pelvic lymphadenectomy in patients undergoing laparoscopic radical prostatectomy [1]. In clinically localized PCa, lymphadenectomy continues to represent a topic of interest and of renewed controversy. Studer and colleagues sensitized the urologic community about the unreliability of limited pelvic lymph node dissection in localized PCa nodal staging [2]. They and others have convincingly demonstrated that the obturator fossa does not represent a safe sentinel site for nodal metastases in all men, regardless of clinical stage, biopsy Gleason sum, and pretreatment serum prostate-specific antigen level. Instead, in at least a proportion of patients, the metastatic spread to lymph nodes occurs through anatomic skip lesions, without affecting the obturator fossa. Studer and colleagues also hinted at a possible survival benefit related to extended lymphadenectomy. However, current data can only confirm a stage migration, when an extended lymphadenectomy is performed instead of a more limited one. The effect of this stage shift spuriously appears to improve the prognosis of men with multiple negative nodes. Indeed, the prognosis is invariably better when more nodes are removed, even in the presence of positive nodes. However, this is exclusively due to stage migration and applies to PCa as well as other malignancies. Briganti and colleagues built on the novel and important findings describing the prevalence and distribution of nodal metastases at radical prostatectomy [3]. They refined the approach to pelvic lymphadenectomy. Specifically, they demonstrated that lymphadenectomies need not be performed in all men. Moreover, they have shown that the decision to perform a lymphadenectomy and the decision about its extent can be tailored according to the individual risk of nodal metastases and their predicted distribution. Nomograms predicting the likelihood of nodal metastases according to the anatomic extent of lymph node dissection or the number of removed and examined lymph nodes represent highly useful tools that can guide the physician in the process of patient selection in the most evidence-based, individualized, and risk-tailored fashion (www. nomogram.org). However, despite the novelty and the controversy, many advances in the field of nodal staging are frequently greeted with initial distrust. A central argument of many clinicians with regard to the importance of pathologic diagnosis of nodal metastases relates to its questionable impact on clinical natural history of treated cancer. What clinicians question the most is the practical impact of positive nodes at radical prostatectomy on patient management. This attitude stems from clinical observations indicating that 25% of men with established nodal metastases will be free of biochemical recurrence 5 yr after
10 1356 european urology 52 (2007) radical prostatectomy, without the use of any secondary therapy [4]. However, among all highrisk patients those with nodal metastases at radical prostatectomy represent the highest risk stratum. Therefore, is radical prostatectomy with delayed intervention the best that we can offer to the 75% who will have treatment failure within 5 yr after radical prostatectomy? Messing et al provided initial highly encouraging findings regarding this particularly high-risk cohort and recently reconfirmed their findings with an updated follow-up. Their results demonstrate an important overall and disease-specific survival benefit, when androgen-deprivation therapy is initiated immediately after radical prostatectomy instead of at the time of clinical disease relapse. Are these survival gains important? The answer is again yes. At 7 yr after prostatectomy, the absolute decrease in causespecific mortality exceeded 30% and the absolute decrease in overall mortality was close to 25%. These findings so far have not been replicated by any other therapeutic modality for patients with high-risk PCa. For example, two contemporary trials of adjuvant radiotherapy for men with pathologically unfavorable PCa at radical prostatectomy failed to demonstrate any statistically significant survival benefit [5]. Therefore, the results of the Messing et al study are fundamental because they indicate in a randomized and controlled fashion that cause-specific and overall survival can be improved in a highly clinically meaningful fashion. However, the most accurate pathologic nodal staging at radical prostatectomy is required to obtain the necessary staging information. Therefore, identification of candidates for nodal staging using nomograms and nomogramguided risk-adjusted approaches to pathologic staging of nodal metastases should continue to represent a central theme in the management of all patients with clinically localized PCa. References [1] Lattouf J-B, Beri A, Jeschke S, Sega W, Leeb K, Janetschek G. Laparoscopic extended pelvic lymph node dissection for prostate cancer: description of the surgical technique and initial results. Eur Urol 2007;52: [2] Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168: [3] Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49: [4] Messing EM, Manola J, Yao J, et al., Eastern Cooperative Oncology Group study. EST 3886: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7: [5] Thompson Jr IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296: DOI: /j.eururo DOI of original article: /j.eururo Editorial Comment on: Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer: Description of the Surgical Technique and Initial Results Fernando J. Bianco Jr. Department of Urology, George Washington University, Washington, DC, USA biancof@gwu.edu This interesting study proposes a surgical technique for an extended laparoscopic pelvic lymph node dissection (PLND) for men with prostate cancer [1]. However, under a cancer control paradigm we do take issue with the concept of extended versus limited dissection. It seems clear in the literature (references 2 6 in the report) that the limited boundaries are well understood and commonly performed, yet fall short because they may identify as much as they miss [2]. Anatomic principles based on historical lymphographic studies suggest that the lymphatic drainage of the prostate flows to nodal tissue contained in the adjacent areas of the inner pelvis. Thus, what is labeled today as extended dissection may represent an appropriate PLND. We should excise no less. This is so unless we test a hypothesis in prospective protocols that seek better patient characterization for this procedure as those pursued in recent evaluations by these investigators and others assessing the value of
11 european urology 52 (2007) sentinel nodes in prostate cancer [1,3]. Nonetheless, we may ask what represents an appropriate anatomic PLND. Clearly, the boundaries suggested in Fig. 1 by this study from Lattouf et al [1] are different from the more established description by Bader et al [2]. These markedly different landmarks handicap scientific reproducibility. Naming or comparing surgical techniques with distinctive anatomic goals makes no sense to us. We have recently shown that in men with prostate cancer, cancer control outcomes depend not only on the cancer characteristics but also on how we perform the surgical procedure, a surrogate of the surgeon s perspective or personal bias, which is acquired from experience to a certain degree. What are the key elements embodied in optimal surgery? Maturing data from larger cohorts have taught us that pelvic node dissections carry much more than prognostic information [2,4,5]. They are curative for a significant number of patients [2,4,5]. Hope shall not be lost if we find a positive node. In fact, survival depends on the number of positive nodes encountered [2], the node-positive density [5], and, in the absence of positive nodes, the number of negative nodes [4]. Historical studies recognized how the lymphatic drainage transits first through the hypogastric tributaries. This region, described as level 3 by Bader et al, harbored exclusive metastases in 19% of their positive nodes [2], an area with compromised anatomic access, greater potential for bleeding, and imperative of surgical exposure. The proposed laparoscopic technique would have spared this nodal tissue and perhaps discounted it as a possible source of cancer recurrence. Although we celebrate the methodology and clear definitions of this well-performed study, we advocate for a standard of care, one that is fair to a patient s interests and cancer control objectives, yet not tailored to a particular technique but otherwise suitable. References [1] Lattouf J-B, Beri A, Jeschke S, Sega W, Leeb K, Janetschek G. Laparoscopic extended pelvic lymph node dissection for prostate cancer: description of the surgical technique and first results. Eur Urol 2007;52: [2] Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514 8, discussion 518. [3] Warncke SH, Mattei A, Fuechsel FG, Z Brun S, Krause T, Studer UE. Detection rate and operating time required for g probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging. Eur Urol 2007;52: [4] Masterson TA, Bianco Jr FJ, Vickers AJ, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:1320 4, discussion [5] Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 2004;172: DOI: /j.eururo DOI of original article: /j.eururo
Radical Perineal Prostatectomy and Simultaneous Extended Pelvic Lymph Node Dissection via the Same Incision
european urology 52 (2007) 384 388 available at www.sciencedirect.com journal homepage: www.europeanurology.com Surgery in Motion Radical Perineal Prostatectomy and Simultaneous Extended Pelvic Lymph Node
More informationGood Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic Prostatectomy
european urology 54 (2008) 344 352 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Good Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic
More informationDavid S. Yee, Darren J. Katz, Guilherme Godoy, Lucas Nogueira, Kian Tai Chong, Matthew Kaag, and Jonathan A. Coleman
Surgical Techniques in Urology Extended Pelvic Lymph Node Dissection in Robotic-assisted Radical Prostatectomy: Surgical Technique and Initial Experience David S. Yee, Darren J. Katz, Guilherme Godoy,
More informationRobotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes
UROLCHI World J Urol DOI 10.1007/s00345-015-1515-6 ORIGINAL ARTICLE Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes Rodrigo A.
More informationUniversity of Zurich. Zurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate
More informationeuropean urology 55 (2009)
european urology 55 (2009) 876 884 available at www.sciencedirect.com journal homepage: www.europeanurology.com Surgery in Motion Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for
More informationRole and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017
Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (2012) 480 487 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by A. Heidenreich on pp. 488 490 of this issue
More informationCurrent status of pelvic lymph node dissection in prostate cancer: the New York PLND nomogram
REVIEW Current status of pelvic lymph node dissection in prostate cancer: the New York PLND nomogram Amir Kazzazi, MD, Bob Djavan, MD Department of Urology, New York University School of Medicine, New
More informationincluding total number of retrieved and positive LNs in each area of dissection, operative duration and complications.
2009 THE AUTHORS. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Laparoscopic and Robotic Urology COMMON ILIAC LYMPH NODE DISSECTION DURING RALP KATZ ET AL. BJUI BJU INTERNATIONAL Lymph node dissection during
More informationL approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo
L approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo Paolo Gontero Division of Urology Città della Salute e della Scienza
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationOpen Radical Cystectomy Tips and Tricks in Males and Females
Open Radical Cystectomy Tips and Tricks in Males and Females Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationeuropean urology 55 (2009)
european urology 55 (2009) 261 270 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by George N. Thalmann on pp. 271 272 of this
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationA specific mapping study using fluorescence sentinel lymph node detection in patients with
1 2 3 A specific mapping study using fluorescence sentinel lymph node detection in patients with intermediate- and high-risk prostate cancer undergoing extended pelvic lymph node dissection 4 5 6 Daniel
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationOde to a node Lymph node dissec3on in prostate and bladder cancer
5/26/10 Ode to a node Lymph node dissec3on in prostate and bladder cancer Anthony Koupparis 1 Introduc3on prostate cancer PLND most accurate and reliable staging method for LNI Imaging techniques have
More informationLYMPH NODE DISSECTION: WHO MAY BE SPARED? Assist. Prof. Dr. Nicolae CRISAN
LYMPH NODE DISSECTION: WHO MAY BE SPARED? Assist. Prof. Dr. Nicolae CRISAN September 2014, Cluj- Napoca GUIDES IN 2003 Role of stadialisamon Lymph node dissecmon N0 N+ Radical prostatectomy Hormonal therapy
More informationOutcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing Radical Prostatectomy
european urology 52 (2007) 1058 1066 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing
More informationLaparoscopic Resection Of Colon & Rectal Cancers. R Sim Centre for Advanced Laparoscopic Surgery, TTSH
Laparoscopic Resection Of Colon & Rectal Cancers R Sim Centre for Advanced Laparoscopic Surgery, TTSH Feasibility and safety Adequacy - same radical surgery as open op. Efficacy short term benefits and
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationUrology Department, Inselspital, Bern, Switzerland. Key Words. Extended pelvic lymph node dissection Bladder cancer Prostate cancer
The Oncologist The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Genitourinary Cancer Indications,
More informationTomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms
european urology 54 (2008) 392 401 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate cancer 11 C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative
More informationThe Template of the Primary Lymphatic Landing Sites of the Prostate Should Be Revisited: Results of a Multimodality Mapping Study
european urology 53 (2008) 118 125 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Template of the Primary Lymphatic Landing Sites of the Prostate Should
More informationPERIOPERATIVE BLOOD LOSS IN OPEN RETROPUBIC RADICAL PROSTATECTOMY IS IT SAFE TO GET OPERATED AT AN EDUCATIONAL HOSPITAL?
292 EUROPEAN JOURNAL OF MEDICAL RESEARCH July 22, 2009 Eur J Med Res (2009) 14: 292-296 I. Holzapfel Publishers 2009 PERIOPERATIVE BLOOD LOSS IN OPEN RETROPUBIC RADICAL PROSTATECTOMY IS IT SAFE TO GET
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationOncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting
END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationRole of Pelvic Lymph Node Dissection in Prostate Cancer Treatment
www.kjurology.org DOI:10.4111/kju.2011.52.7.437 Review Article Role of Pelvic Lymph Node Dissection in Prostate Cancer Treatment Jae Young Joung, In-Chang Cho, Kang Hyun Lee Center for Prostate Cancer,
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationPotency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery
Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery F Van der Aa 1, S Joniau 1, D De Ridder 1 & H Van Poppel 1 * 1 Department
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
2692 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(14): 2692-2698. doi: 10.7150/jca.20409 Updated Nomogram Incorporating Percentage of Positive Cores to Predict Probability
More informationComparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy
Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationA Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationda Vinci Prostatectomy My Greek personal experience
da Vinci Prostatectomy My Greek personal experience Vassilis Poulakis MD, PhD, FEBU Ass. Prof. of Urology Director of Urologic Clinic Doctors Hospital Athens Laparoscopy - golden standard in Urology -
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationOriginal Paper. Urol Int 2015;95: DOI: /
Urologia Internationalis Original Paper Published online: July 3, 2015 First Nomogram Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients Undergoing Radioisotope Guided Sentinel
More informationRadical Prostatectomy and Pelvic Lymph Node Dissection in Kaiser Permanente Southern California: 15-Year Experience
Radical Prostatectomy and Pelvic Lymph Node Dissection in Kaiser Permanente Southern California: 15-Year Experience Pooya Banapour, MD 1 ; Andrew Schumacher, MD 2 ; Jane C Lin 3 ; David S Finley, MD 1
More informationFIG The inferior and posterior peritoneal reflection is easily
PSOAS HITCH, BOARI FLAP, AND COMBINATION OF PSOAS 7 HITCH AND BOARI FLAP The psoas hitch procedure, Boari flap, and transureteroureterostomy are useful operative procedures for reestablishing continuity
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationLymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic
Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationMRI and metastases of PCa
MRI and metastases of PCa François CORNUD Céline COUVIDAT David EISS Arnaud LEFEVRE IRM Paris 16, France, Paris, France Université Paris Descartes, Paris, France When imaging should be considered for detection
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationInvasion of the muscular wall of the seminal vesicles by prostate cancer is generally
PROSTATE CANCER Seminal Vesicle Invasion by Prostate Cancer: Prognostic Significance and Therapeutic Implications Steven R. Potter, MD,* Jonathan I. Epstein, MD,* Alan W. Partin, MD, PhD* *The James Buchanan
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationLymph node dissection: how much is enough?
1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationThe Role of Lymphography in 11 Apparently Localized" Prostatic Carcinoma
16 Lymphology 8 (1975) 16-20 Georg Thieme Verlag Stuttgart The Role of Lymphography in 11 Apparently Localized" Prostatic Carcinoma R. A. Castellino - Department of Radiology, Stanford-University School
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationOncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
european urology 55 (2009) 404 411 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
More informationPathologic Outcomes during the Learning Curve for Robotic-Assisted Laparoscopic Radical Prostatectomy
Clinical Urology Pathologic Outcomes While Learning RALP International Braz J Urol Vol. 34 (2): 159-163, March - April, 2008 Pathologic Outcomes during the Learning Curve for Robotic-Assisted Laparoscopic
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationDepartment of Urology, Washington DC Veterans Affairs Medical Center, Washington, DC, USA 4
Original Article Prostate Int 2013;1(1):31-36 P R O S T A T E INTERNATIONAL Robotic-assisted prostatectomy and open radical retropubic prostatectomy for locally-advanced prostate cancer: multi-institution
More informationRetroperitoneal Laparoscopic Radical Nephroureterectomy for High Urothelial Tumours
Retroperitoneal Laparoscopic Radical Nephroureterectomy for High Urothelial Tumours A. Hașegan 1, V. Pîrvuț 1, I. Mihai 1, N. Grigore 1 1 Lucian Blaga University of Sibiu, Faculty of Medicine Clinical
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationincision into an otherwise organ-confined cancer [1,5].
28 The Authors. Journal compilation 28 BJU International Original Article IMPACT ON PROGRESSION OF POSITIVE SURGICAL MARGINS AFTER RP PFITZENMAIER et al. BJUI BJU INTERNATIONAL Positive surgical margins
More informationESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data
ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data David Cibula Gynecologic Oncology Centre General University Hospital
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationmid-term follow-up of 1115 procedures
1 2 3 Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: mid-term follow-up of 1115 procedures 4 5 6 7 8 9 Alexandre Paul*, Guillaume Ploussard*, Nathalie Nicolaiew, Evanguelos
More information